View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsHanulBnCLTD 배당 및 자사주 매입배당 기준 점검 0/6HanulBnCLTD 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률2.3%자사주 매입 수익률총 주주 수익률2.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 14HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 289, jangmal-ro, gyeonggi-do, bucheon South Korea공시 • Mar 05NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsOn March 4, 2024, NewGLAB Pharma CO.,LTD closed the transaction.공시 • Feb 23NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsNewGLAB Pharma CO.,LTD announced a private placement to issue 13,670,000 common shares at an issue price of KRW 500 per share for the gross proceeds of KRW 6,835,000,000 on February 22, 2024. The transaction included participation from new investors H&Y Holdings Co., Ltd. 5,600,000 shares, APIC Co., Ltd. 2,000,000 shares, Namu Invest Co., Ltd. 800,000 shares, Namhwa Corporation 400,000 shares and SLP Co. Ltd. 400,000 shares and individual investors OO Kim for 1,120,000 shares, OO Yoon 2,000,000 shares, OO 400,000 shares, LeeOO 400,000 shares and Seo OO 150,000 shares. The transaction has been approved by the shareholders of the company and is expected to closed on March 4, 2024. The securities are restricted to a hold period.Reported Earnings • Mar 18Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021)Full year 2022 results: ₩2,201 loss per share (further deteriorated from ₩1,662 loss in FY 2021). Revenue: ₩21.7b (down 26% from FY 2021). Net loss: ₩69.6b (loss widened 38% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 49% per year, which means it has not declined as severely as earnings.Buying Opportunity • Aug 24Now 25% undervaluedOver the last 90 days, the stock is up 38%. The fair value is estimated to be ₩17,476, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 56%.공시 • Apr 07NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmOn April 5, 2022, NewGLAB Pharma CO.,LTD closed the transaction.공시 • Mar 23NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in fundingOn March 22, 2021, NewGLAB CO.,LTD (KOSDAQ:A214870) closed the transaction.Reported Earnings • Mar 17Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩54.4b (down 43% from FY 2019). Net loss: ₩22.6b (loss widened 464% from FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.공시 • Mar 14NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in fundingNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 7 non-guaranteed private convertible bonds with bearer interest with for gross proceeds of KRW 9,230,000,000 on March 12, 2021. The transaction will include participation from Hyun-cheol Noh for KRW 3,230,000,000 and Seong-su Cho for KRW 6,000,000,000. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on March 22, 2024. The bonds are 100% convertible into 699,242 shares, representing 2.28%, at a fixed conversion price of KRW 13,200 per share. The conversion period starts from March 22, 2022 and ends on February 22, 2024. The subscription date is March 12, 2021 and the transaction is expected to close on March 22, 2021. The transaction has been approved by the company's board of directors. The bonds carry a hold period of one year.Is New 90 Day High Low • Feb 18New 90-day low: ₩10,900The company is down 15% from its price of ₩12,850 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 41% over the same period.Is New 90 Day High Low • Jan 27New 90-day low: ₩11,850The company is down 12% from its price of ₩13,500 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 57% over the same period.분석 기사 • Dec 22The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...Is New 90 Day High Low • Nov 11New 90-day low: ₩12,750The company is down 4.0% from its price of ₩13,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 3.0% over the same period.공시 • Sep 29NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 6 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 35,000,000,000 on September 28, 2020. The transaction will include participation from returning investor DB Financial Investment Co.,Ltd., Investment Arm. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on October 20, 2023. The bonds are 100% convertible into 2,287,432 shares, representing 7.29%, at a fixed conversion price of KRW 15,301 per share. The conversion period starts from October 20, 2021 and ends on September 20, 2023. The subscription date is September 28, 2020 and the transaction is expected to close on October 20, 2020. The transaction has been approved by the company's board of directors.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A214870 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A214870 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장HanulBnCLTD 배당 수익률 vs 시장A214870의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A214870)n/a시장 하위 25% (KR)1.0%시장 상위 25% (KR)3.8%업계 평균 (Electronic)0.3%분석가 예측 (A214870) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A214870 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A214870 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A214870 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A214870 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/04/01 22:25종가2025/03/28 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스HanulBnC CO.,LTD는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jongsun ParkEugene Investment & Securities Co Ltd.
공시 • Mar 14HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 289, jangmal-ro, gyeonggi-do, bucheon South Korea
공시 • Mar 05NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsOn March 4, 2024, NewGLAB Pharma CO.,LTD closed the transaction.
공시 • Feb 23NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investorsNewGLAB Pharma CO.,LTD announced a private placement to issue 13,670,000 common shares at an issue price of KRW 500 per share for the gross proceeds of KRW 6,835,000,000 on February 22, 2024. The transaction included participation from new investors H&Y Holdings Co., Ltd. 5,600,000 shares, APIC Co., Ltd. 2,000,000 shares, Namu Invest Co., Ltd. 800,000 shares, Namhwa Corporation 400,000 shares and SLP Co. Ltd. 400,000 shares and individual investors OO Kim for 1,120,000 shares, OO Yoon 2,000,000 shares, OO 400,000 shares, LeeOO 400,000 shares and Seo OO 150,000 shares. The transaction has been approved by the shareholders of the company and is expected to closed on March 4, 2024. The securities are restricted to a hold period.
Reported Earnings • Mar 18Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021)Full year 2022 results: ₩2,201 loss per share (further deteriorated from ₩1,662 loss in FY 2021). Revenue: ₩21.7b (down 26% from FY 2021). Net loss: ₩69.6b (loss widened 38% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 49% per year, which means it has not declined as severely as earnings.
Buying Opportunity • Aug 24Now 25% undervaluedOver the last 90 days, the stock is up 38%. The fair value is estimated to be ₩17,476, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 56%.
공시 • Apr 07NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmOn April 5, 2022, NewGLAB Pharma CO.,LTD closed the transaction.
공시 • Mar 23NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in fundingOn March 22, 2021, NewGLAB CO.,LTD (KOSDAQ:A214870) closed the transaction.
Reported Earnings • Mar 17Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩54.4b (down 43% from FY 2019). Net loss: ₩22.6b (loss widened 464% from FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Mar 14NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in fundingNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 7 non-guaranteed private convertible bonds with bearer interest with for gross proceeds of KRW 9,230,000,000 on March 12, 2021. The transaction will include participation from Hyun-cheol Noh for KRW 3,230,000,000 and Seong-su Cho for KRW 6,000,000,000. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on March 22, 2024. The bonds are 100% convertible into 699,242 shares, representing 2.28%, at a fixed conversion price of KRW 13,200 per share. The conversion period starts from March 22, 2022 and ends on February 22, 2024. The subscription date is March 12, 2021 and the transaction is expected to close on March 22, 2021. The transaction has been approved by the company's board of directors. The bonds carry a hold period of one year.
Is New 90 Day High Low • Feb 18New 90-day low: ₩10,900The company is down 15% from its price of ₩12,850 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 41% over the same period.
Is New 90 Day High Low • Jan 27New 90-day low: ₩11,850The company is down 12% from its price of ₩13,500 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 57% over the same period.
분석 기사 • Dec 22The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Is New 90 Day High Low • Nov 11New 90-day low: ₩12,750The company is down 4.0% from its price of ₩13,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 3.0% over the same period.
공시 • Sep 29NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment ArmNewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 6 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 35,000,000,000 on September 28, 2020. The transaction will include participation from returning investor DB Financial Investment Co.,Ltd., Investment Arm. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on October 20, 2023. The bonds are 100% convertible into 2,287,432 shares, representing 7.29%, at a fixed conversion price of KRW 15,301 per share. The conversion period starts from October 20, 2021 and ends on September 20, 2023. The subscription date is September 28, 2020 and the transaction is expected to close on October 20, 2020. The transaction has been approved by the company's board of directors.